Henry Schein, Inc. HSIC

MELVILLE, N.Y., September 30, 2026--Henry Schein Cares, Henry Schein, Inc.’s global corporate citizenship program, is celebrating a quarter century of bringing together Team Schein Members, customers, supplier partners, healthcare professionals, nonprofit organizations, and communities to help make the world healthier.

Henry Schein trades at $86.39 and has moved in lockstep with the market. Its shares have returned 18.8% over the last six months while the S&P 500 has gained 21.4%.

Henry Schein (HSIC) is back in focus after amending and restating its revolving credit facility, increasing total commitments to $1.25 billion and extending the termination date to September 19, 2031. Against that backdrop, Henry Schein’s share price has moved to $86.37, with a 1-day share price return of 0.98% and a 7-day share price return of 1.80%. The 30-day share price return declined 3.52%, and the year-to-date share price return is 12.43%. The 1-year total shareholder return of 30.74%...

Henry Schein has delivered a 30.7% share price gain over the past year, which naturally puts the spotlight on whether that move is backed by the cash the business is expected to generate. With the stock recently closing at US$86.37, the key issue now is how that price lines up against the value suggested by its cash flows. The 30.7% return over the past 12 months raises a straightforward question for holders and potential buyers: whether the cash that Henry Schein can produce is enough to...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Henry Schein has outperformed the Dow over the past year, and analysts are cautiously optimistic about the stock’s prospects.

MIAMI, September 09, 2026--DermaSensor Inc., a leader in AI-powered skin cancer diagnostic technology, announced today the close of a $4M Series B extension, including institutional and strategic investors, alongside the launch of a community investment round on Wefunder. This new community financing has already raised more than $1 million at the same terms as the $4M. This follows the company’s $16M Series B, closed in 2025, and brings the total investment in the company to $48 million.

MELVILLE, N.Y., September 08, 2026--Henry Schein, Inc., the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that the Company will present at the following conference in September:

Henry Schein stock performance snapshot Henry Schein (HSIC) stock has drawn investor attention after recent share price moves, with the company reporting positive total returns over the past year and across multi year periods, alongside reported revenue and net income growth. At the latest share price of US$88.52, Henry Schein has given investors a 16.9% share price return over the past 90 days and a 29.4% total shareholder return over the past year. This suggests momentum has been building...

MIAMI, September 01, 2026--DermaSensor Inc., a leader in AI-powered skin cancer diagnostic technology, today announced a major expansion of its U.S. commercial strategy through a series of strategic partnerships to accelerate adoption of its FDA cleared, handheld skin cancer detection device across primary care, enterprise healthcare, and federal healthcare systems.

MD Sass, a boutique asset management firm, published its second-quarter investor update for its flagship, the “MD Sass Concentrated Value Strategy.” The letter can be downloaded here. In the first half of 2026, AI infrastructure stocks led the market, with the Russell 1000 Value increasing by 16.3%, outpacing the S&P 500 (10.2%) and Russell 1000 […]